Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.


Journal

Neuro endocrinology letters
ISSN: 2354-4716
Titre abrégé: Neuro Endocrinol Lett
Pays: Sweden
ID NLM: 8008373

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 17 01 2020
accepted: 23 02 2020
pubmed: 28 4 2020
medline: 26 8 2021
entrez: 28 4 2020
Statut: ppublish

Résumé

Neurofilament light chain (NfL) is considered a major marker of neurodegeneration and disease activity. Higher levels of NfL are associated with worse clinical outcomes and increased brain atrophy. In treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS), we aimed to determine the level of NfL, an association between NfL and demographic, clinical and magnetic resonance imaging (MRI) characteristics as well as brain volume parameters. We wanted to confirm that level of NfL is clinically useful as biomarker of neurodegeneration and disease activity. 56 treated RRMS patients were enrolled. Plasmatic levels of NfL (pNfL) were measured by SIMOA® technique. Clinical severity of MS was expressed by Expanded Disability Status Scale (EDSS), and volumetric analysis of MRI data was performed using Icobrain software. The mean pNfL level was significantly higher in MS patients than in healthy controls (14.73 ± 6.38 versus 6.67 ± 3.9, p<0.001). In patients, we did not find association between pNfL and MRI activity, number of new T2 lesions, and number of enhancing lesions. Levels of pNfL correlated significantly with atrophy of whole brain volume (Wbv), atrophy of grey matter volume (Gmv), and negatively with Wbv. We found significantly positive correlation between pNfL levels and EDSS. Study shows association of pNfL with Wbv, presence of brain atrophy and EDSS, and strong correlation of EDSS with multiple MRI volume parameters. We did not confirm association pNfL with disease activity. Our data suggest that pNfL and MRI volume parameters could be considered as biomarkers of neurodegeneration in MS.

Sections du résumé

BACKGROUND BACKGROUND
Neurofilament light chain (NfL) is considered a major marker of neurodegeneration and disease activity. Higher levels of NfL are associated with worse clinical outcomes and increased brain atrophy. In treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS), we aimed to determine the level of NfL, an association between NfL and demographic, clinical and magnetic resonance imaging (MRI) characteristics as well as brain volume parameters. We wanted to confirm that level of NfL is clinically useful as biomarker of neurodegeneration and disease activity.
METHODS METHODS
56 treated RRMS patients were enrolled. Plasmatic levels of NfL (pNfL) were measured by SIMOA® technique. Clinical severity of MS was expressed by Expanded Disability Status Scale (EDSS), and volumetric analysis of MRI data was performed using Icobrain software.
RESULTS RESULTS
The mean pNfL level was significantly higher in MS patients than in healthy controls (14.73 ± 6.38 versus 6.67 ± 3.9, p<0.001). In patients, we did not find association between pNfL and MRI activity, number of new T2 lesions, and number of enhancing lesions. Levels of pNfL correlated significantly with atrophy of whole brain volume (Wbv), atrophy of grey matter volume (Gmv), and negatively with Wbv. We found significantly positive correlation between pNfL levels and EDSS.
CONCLUSION CONCLUSIONS
Study shows association of pNfL with Wbv, presence of brain atrophy and EDSS, and strong correlation of EDSS with multiple MRI volume parameters. We did not confirm association pNfL with disease activity. Our data suggest that pNfL and MRI volume parameters could be considered as biomarkers of neurodegeneration in MS.

Identifiants

pubmed: 32338853
pii: NEL410120A02

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17-26

Auteurs

Pavol Filippi (P)

1st Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Veronika Vestenická (V)

1st Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Pavel Siarnik (P)

1st Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Monika Sivakova (M)

1st Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Daniela Čopíková-Cudráková (D)

1st Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Víťazoslav Belan (V)

Dr. Magnet - Kramáre, Bratislava, Slovakia.

Jozef Hanes (J)

Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia.

Michal Novák (M)

Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia.

Branislav Kollar (B)

1st Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Peter Turcani (P)

1st Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH